Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

In its third-quarter 2024 earnings report, Sangamo announced significant achievements, including a regulatory pathway for accelerated approval of a Fabry disease treatment and promising collaborative ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline ...

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma #782 oral presentation ...

The Hillsboro Herald regularly tracks the happenings at Hillsboro City Hall, at least to the best of our ability we ...

The United States is home to one of the leading healthcare systems globally, primarily due to its remarkable ability to drive ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...